MMAE Products

MMAE Full Name

Monomethyl auristatin E

MMAE Introduction

Monomethyl auristatin E (MMAE) is a potent cytotoxic agent commonly used in antibody-drug conjugates (ADCs) for targeted cancer therapy. Upon binding to CD30-expressing cells, the ADC-CD30 complex is internalized, leading to the release of MMAE via proteolytic cleavage. Antibody-drug conjugates (ADCs) are an emerging class of targeted therapies for the treatment of cancer that aim to directly deliver small molecule chemotherapy and kill tumor cells while sparing healthy cells. ADCs mainly contain three parts: monoclonal antibodies, linkers and toxins. Monoclonal antibodies are the key to determining the efficacy of ADC; the linker determines the systemic toxicity and clinical efficacy of ADC drugs; toxins are the key factor that determines the lethality of ADC drugs. Although there are currently more than 130 types of toxins used in announced ADC drugs, there are only 6-8 toxins used in ADC drugs that are in clinical trials or have been marketed. According to the mode of action, they can be roughly divided into three categories: tubulin inhibitors, DNA synthesis inhibitors and topoisomerase inhibitors. Among them, ADC drugs using MMAE in tubulin inhibitors as toxin molecules have been approved the most. Today we focus on the definition of MMAE and its application and mechanism of action in ADC.

In preclinical studies, MMAE has exhibited promising antitumor activity in various cancer models, including prostate cancer, pancreatic cancer, and gastric cancer. Additionally, MMAE conjugates have shown improved therapeutic indices compared to free MMAE, as evidenced by a 10-fold increase in the maximum tolerated dose for PSMA-1-VcMMAE in comparison to PSMA-ADC. Moreover, the use of MMAE-linked ADCs targeting tumor endothelial marker 8 (TEM8) has been described, highlighting the potential of MMAE in stromal-targeted cancer therapy. However, it is important to note that MMAE's high toxicity necessitates precise targeting to tumors to minimize off-target effects. Studies have explored various strategies to achieve this, including the development of peptide conjugates and ADCs. Additionally, the use of protease-cleavable linkers in ADCs has been shown to modulate the anticancer activity of non-internalizing ADCs, leading to the release of MMAE in the subendothelial extracellular matrix, thereby enhancing their anti-cancer activity.

In conclusion, the potent cytotoxicity of MMAE, when harnessed in ADCs, holds great promise for targeted cancer therapy. However, the development of precise targeting strategies and the use of cleavable linkers are crucial for maximizing its therapeutic potential while minimizing systemic toxicity.

Alternate Names for MMAE

Monomethyl auristatin E
MMAE Antibody Drug Conjugate
MMAE

• MMAE Antibodies
• MMAE ELISA Kits
• MMAE Antigens
• Cytotoxic Drug Antibodies
• Anti-MMAE (Monomethyl auristatin E) Antibodies and MMAE Conjugates: For PK/PD Studies on MMAE-ADC

Protease-mediated cleavage is needed for MMAE release

Researcher investigated whether cathepsin B cleavage of a valine–citrulline [VC(S)]-containing linker is required for the release of monomethyl auristatin E (MMAE) from albumin–drug conjugates. In this study, they used an engineered version of human serum albumin, Veltis High Binder II (HBII), which has enhanced binding to the neonatal Fc (fragment crystallizable) receptor (FcRn) to improve drug release upon binding and FcRn-mediated recycling. The linker–payload was conjugated to cysteine 34 of albumin using a carbonylacrylic (caa) reagent which produced homogeneous and plasma stable conjugates that retained FcRn binding. Two caa–linker–MMAE reagents were synthesized─one with a cleavable [VC(S)] linker and one with a noncleavable [VC(R)] linker─to question whether protease-mediated cleavage is needed for MMAE release.

The findings demonstrate that cathepsin B is required to achieve efficient and selective antitumor activity. The conjugates equipped with the cleavable [VC(S)] linker had potent antitumor activity in vivo facilitated by the release of free MMAE upon FcRn binding and internalization. In addition to the pronounced antitumor activity of the albumin conjugates in vivo, researchers also demonstrated their preferable tumor biodistribution and biocompatibility with no associated toxicity or side effects. These results suggest that the use of engineered albumins with high FcRn binding combined with protease cleavable linkers is an efficient strategy to target delivery of drugs to solid tumors.

Since ADC toxins are highly cytotoxic, PK studies of ADC payloads are important to understand the behavior of the payload. However, due to the high toxicity of MMAE itself, such studies are not allowed in humans. Therefore, it is very important to detect MMAE levels preclinically (such as measuring the concentration of ADC and conjugated MMAE). Creative Diagnostics has developed anti-MMAE antibodies suitable for ADC ELISA determination. It can be used to quantitatively determine the level of anti-MMAE-conjugates in test samples. It can be used for PK detection and DAR value analysis to accelerate the development process of ADC drugs.

• Anti-Cytotoxic Payloads Antibodies
• High Quality Reagents for MMAE ADC Research and Development
• Immunoassay of Antibody-Drug Conjugates (ADCs)
• Tools for ADCs PK Analysis

• 1. Barbara Bernardim., et al. Cathepsin B Processing Is Required for the In Vivo Efficacy of Albumin–Drug Conjugates. Bioconjugate Chemistry Article ASAP. 2024